Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Molecular Oncology|May 23, 2025
TRPM8 levels determine tumor vulnerability to channel agonistsAlessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, et al.
Lung Cancer (Amsterdam, Netherlands)|October 14, 2019
Prognostic factors after treatment for iterative thymoma recurrences: A multicentric experienceMarco Chiappetta, Edoardo Zanfrini, Luca Giraldi, et al.
Cancer Medicine|July 20, 2024
Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER studyIrene Dogliotti, Veronica Peri, Michele Clerico, et al.
Cells|August 9, 2020
Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder CancerDafina Ilijazi, Walter Pulverer, Iris E Ertl, et al.
Cancer Cell|December 1, 2023
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cellsElisa Bergaggio, Wei-Tien Tai, Andrea Aroldi, et al.
Frontiers in Oncology|October 23, 2023
Cohort profile: the Turin prostate cancer prognostication (TPCP) cohortNicolas Destefanis, Valentina Fiano, Lorenzo Milani, et al.
Leukemia|October 18, 2024
Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistanceClarissa Corinaldesi, Antony B Holmes, Gaia Martire, et al.
The Journal of Molecular Diagnostics : JMD|January 1, 2014
MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissueAnna Sapino, Paul Roepman, Sabine C Linn, et al.
Cancer Discovery|May 16, 2012
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancerAndrea Bertotti, Giorgia Migliardi, Francesco Galimi, et al.
Blood Advances|October 9, 2021
Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphomaChiara Pighi, Taek-Chin Cheong, Mara Compagno, et al.
Pageof 7